Related Experiment Video
Updated: Jun 6, 2026
10:16
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Recent developments in therapeutic approaches for lysosomal storage diseases
Lorena Urbanelli1, Alessandro Magini, Alice Polchi
1Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Via del Giochetto, 06126 Perugia, Italy.
Recent Patents on CNS Drug Discovery
|November 16, 2010
Summary
Lysosomal Storage Diseases (LSDs) treatments are evolving beyond enzyme replacement therapy (ERT). Novel approaches like small molecules and gene therapy offer new hope for these rare genetic disorders.
Area of Science:
- Biochemistry and Genetics
- Neuroscience
- Pharmacology
Background:
- Lysosomal Storage Diseases (LSDs) are a group of over 45 genetic disorders caused by lysosomal protein deficiencies.
- These diseases often manifest in pre-adulthood, presenting with neurological symptoms and cognitive impairment.
- Pathological hallmarks include intracellular deposition and protein aggregation, mirroring aspects of age-related neurodegenerative diseases.
Purpose of the Study:
- To review the current landscape of therapeutic strategies for Lysosomal Storage Diseases.
- To highlight recent advancements and emerging treatments, including novel therapeutic options and recent patents.
Main Methods:
- Review of existing literature on Lysosomal Storage Diseases treatments.
- Analysis of therapeutic approaches including enzyme replacement therapy (ERT), substrate reduction therapy, pharmacological chaperones, gene therapy, and stem cell-based strategies.
- Inclusion of recent patent information in the field.
Main Results:
- Enzyme Replacement Therapy (ERT) has been a significant advancement but faces limitations in enzyme distribution and high costs.
- Emerging therapies include small molecules for substrate reduction or chaperone activity, and gene therapy using viral vectors.
- Stem cell-based strategies are also under development.
Conclusions:
- The therapeutic landscape for LSDs is rapidly expanding beyond traditional ERT.
- Pharmacological chaperones, substrate reduction, gene therapy, and stem cell approaches represent promising avenues for improved treatment outcomes.
- Continued research and patent activity indicate a dynamic field focused on addressing the challenges of LSDs.
Related Concept Videos
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:36Delivery Pathways to the Lysosome
Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
01:31Lysosomes
Lysosomes are membrane-enclosed spherical sacs derived from the Golgi apparatus. The most important function of the lysosome is degrading macromolecules and biological polymers that are released during membrane trafficking events such as the secretory, endocytic, autophagic, and phagocytic pathways. The degradation is carried out by several hydrolytic enzymes active in an acidic environment of the lysosomal lumen. These acid hydrolases are involved in cellular processes such as cell signaling,...
01:31Lysosomes
Lysosomes are membrane-enclosed spherical sacs derived from the Golgi apparatus. The most important function of the lysosome is degrading macromolecules and biological polymers that are released during membrane trafficking events such as the secretory, endocytic, autophagic, and phagocytic pathways. The degradation is carried out by several hydrolytic enzymes active in an acidic environment of the lysosomal lumen. These acid hydrolases are involved in cellular processes such as cell signaling,...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...